Erectile dysfunction as a consequence of somatic diseases and its treatment

Česká verzia

Authors: T. Šrámková
Authors place of work: Sexuologické oddělení FN Brno ; Urologická klinika a Sexuologický ústav 1. LF UK a VFN Praha
Published in the journal: Urol List 2014; 12(1): 15-18

Summary

Erectile dysfunction can be an early clinical marker for the presence of endothelial dysfunction, systemic vascular abnormalities including coronary artery disease. Erectile dysfunction is a predictor of a serious cardiovascular event in men aged 30– 60 years and in diabetics, the time interval is 2– 5 years. Erectile dysfunction is highly prevalent in type two diabetes mellitus in 75%. Erectile dysfunction is associated with oncological diseases – colorectal and prostate carcinoma. Spinal cord injury and pelvic injury are associated with neurogenic erectile dysfunction. The modern oral therapy for erectile dysfunction therapy using PDE5 inhibitors and intracavernosal therapy using Alprostadil is safe, effective and is well tolerated. Oral or intracavernosal penile rehabilitation therapy is indicated especially in oncological patients in prevention of irreversible damage of cavernosal tissue.

Key words:
erectile dysfunction, endothelial dysfunction, cardiovascular diseases, diabetes mellitus, oncological diseases, spinal cord injury and pelvic injury, therapy, penile rehabilitation

Zdroje

1. Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151(1): 54– 61.

2. Weiss P, Zvěřina J. Sexuální chování obyvatel ČR IV.Srovnání výzkumů z let 1993, 1998, 2003, 2008. 1. ed. Praha: DEMA 2009.

3. Šrámková T. Poruchy sexuality u somatických onemocnění a jejich léčba. Praha: Grada‑ Publishing 2013.

4. Santos T, Drummond M, Botelho F. Erectile dysfunction in obstructive sleep apnea syndrome – prevalence and determinants. Rev Port Pneumol 2012; 18(2): 64– 71. doi: 10.1016/ j.rppneu.2011.10.004.

5. Pohanka M, Stárka L. Erektilní dysfunkce a jejich léčba. Praha: Maxdorf 2011.

6. Jackson G. Prediction of coronary artery disease by erectile function status: evidence‑based data. Sex Med Rev 2013; 1(2): 104– 107. doi: 10.1002/ smrj.12.

7. Costa C, Virag R. The endothelial‑ erectile dysfunction connection: an essential update. J Sex Med 2009; 6(9): 2390– 2404. doi: 10.1111/ j.1743- 6109.2009.01356.x.

8. Kirby M, Jackson G, Betteridge J et al. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Prakt 2001; 55(9): 614– 618.

9. Montorsi P, Ravagnani P, Galli S et al. The artery size hypotheisis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol 2005; 96(12B): 19M–23M.

10. Avasthi A, Grover S, Bhansali A et al. Erectile dysfunction in diabetes mellitus contributes to poor quality of life. Int Rev Psychiatry 2011; 23(1): 93– 99. doi: 10.3109/ 09540261.2010.545987.

11. Sáenz de Tejada I, Anglin G, Knight J et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25(12): 2159– 2164.

12. Wang C, Jackson G, Jones TH et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 2011; 34(7): 1669– 1675. doi: 10.2337/ dc10- 2339.

13. Katz A. Multiple sclerosis and sexuality. Am J Nurs 2011; 111(7): 65– 68. doi: 10.1097/ 01.NAJ.0000399319.10977.2d.

14. Pocard M, Zinzindohoue F, Haab F et al. A prospective study of sexual and urinary function before and after total mesorectal excision with autonomic nerve preservation for rectal cancer. Surgery 2002; 131(4): 368– 372.

15. Gallina A, Briganti A, Suardi N et al. Surgery and erectile dysfunction. Arch Esp Urol 2010; 63(8): 640– 648.

16. Salonia A, Burnett AL, Graefen M et al. Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery. Eur Urol 2012; 62(2): 261– 272. doi: 10.1016/ j.eururo.2012.04.046.

17. Mendenhall WM, Henderson RH, Indelicato DJ et al.Erectile dysfunction after radiotherapy for prostate cancer. Am J Clin Oncol 2009; 32(4): 443– 447. doi: 10.1097/ COC.0b013e318173a563.

18. Collins L, Basaria S. Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications. Asian J Androl 2012; 14(2): 222– 225. doi: 10.1038/ aja.2011.109.

19. Salonia A, Burnett AL, Graefen M et al. Prevention and management of postprostatectomy sexual dysfunction part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol 2012; 62(2): 273– 286. doi: 10.1016/ j.eururo.2012.04.047.

20. Zámečník L et al. Praktická andrologie dospělých. 1. ed. Praha: Mladá fronta 2010.

21. Oelke M, Giuliano F, Mirone V et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international randomised, parallel, placebo‑ controlled clinical trial. Eur Urol 2012; 61(5): 917– 925. doi: 10.1016/ j.eururo.2012.01.013.

22. Sramkova T, Fajtova R. Sexual life after spinal cord injury. In: Tanya C. Berkovsky: Handbook of spinal cord injuries: types, treatments and prognosis. New York: Nova Science Publishers 2010: 133– 166.

23. Machtens S, Gänsslen A, Pohlemann T et al. Erectile dysfunction in relation to traumatic pelvic injuries or pelvic fractures. BJU Int 2001; 87(5): 441– 448.

24. Wespes E, Eardley I, Giuliano F et al. Male sexual dysfunction: erectile dysfunction and premature ejaculation. Guidelines EAU 2013. Available from: http:/ / www.uroweb.org/ guidelines/ online‑ guidelines/ ?no_cache=1.

25. Souhrn informací o přípravku. SÚKL. Dostupné z: www.sukl.cz/ modules/ medication.

26. Goldstein I, McCullough AR, Jones LA et al. A randomized, double‑blind, placebo‑ controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med 2012; 9(4): 1122– 1133. doi: 10.1111/ j.1743- 6109.2011.02629.x.

27. Aversa A, Vitale C, Volterrani M et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med 2008; 25(1): 37– 44. doi: 10.1111/ j.1464- 5491.2007.02298.x.

28. Foresta C, Ferlin A, De Toni L et al. Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 2006; 18(5): 484– 488.

29. Wang C, Jackson G, Jones TH et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 2011; 34(7): 1669- 1675. doi: 10.2337/ dc10– 2339.

30. Wyllie MG. Monotherapy for comorbid erectile dysfunction and lower urinary tract symptoms: phosphodiesterase inhibitor or a‑adrenoceptor antagonist? BJU Int 2012; 109(7): 965– 966. doi: 10.1111/ j.1464- 410X.2012.10984.x.

31. Gruenwald I, Kitrey ND, Appel B et al. Low‑ intensity extracorporeal shock wave therapy in vascular disease and erectile dysfunction: theory and outcomes. Sex Med Rev 2013; 1: 83– 90.

32. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334(14): 873– 877.

33. Heaton JP, Lording D, Liu SN et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 2001; 13(6): 317– 321.

34. Pacík D. Chirurgické řešení erektilní dysfunkce implantací penilní protézy. Andrologie 2003; 4: 25– 30.

35. Trost LW, Hellstrom WJ. History, contemporary outcomes, and future of penile prostheses: a review of the literature. Sex Med Rev 2013; 1: 150– 163.